MedWatch

Bavarian Nordic enters license agreement with Nuance Pharma on RSV candidate

Nuance Pharma, a Shanghai-based biotech company, gains the commercial rights in a string of Asian countries for Bavarian Nordic’s RSV vaccine candidate.

Photo: Bavarian Nordic / PR

On Monday, Bavarian Nordic announced that a license and supply agreement has been completed with Shanghai-based biotech company Nuance Pharma, regarding the rights for the Danish company’s RSV vaccine candidate, a stock notification reports.

Bavarian is set to receive an upfront payment of USD 12.5m, and the deal also entails potential milestone payments of up to USD 212.5m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs